Results
Alivus Life Sciences Q4 FY26 EBITDA Margin Hits 34.4%
Alivus Life Sciences reported Q4 FY26 revenue of INR689 crore, up 6.1% YoY, with EBITDA margin expanding 230 bps to 34.4%.
Full-year FY26 revenue grew 6.9% to INR2,552 crore with EBITDA margin reachin
